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 The authors used human and rat muscle to
study the mechanism of statin myopathy
and its interaction with exercise.
 Statin treatment triggered loss of the
modulatorprotein FKBP fromthe sarcoplasmic
reticulum (SR) calcium (Ca2D) release channel,
ryanodine receptor 1 (RyR1).
 Loss of FKBP was associated with reactive
nitrogen species/reactive oxygen
species-dependent SR Ca2D leak and
pro-apoptotic signaling, but had no overt
impact on muscle function.
 Moderate running wheel exercise
prevented the effects of statin treatment
on the FKBP/RyR complex, SR Ca2D leak,
and pro-apoptotic signaling.
 Our data show that statin treatment
induces a potentially harmful SR Ca2D
leak that might trigger statin myopathy in
susceptible individuals, but could be
prevented by moderate exercise.https://doi.org/10.1016/j.jacbts.2019.03.012
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ABBR EV I A T I ON S
AND ACRONYMS
Ca2þ = calcium
FDB = ﬂexor digitorum brevis
FKBP12 = FK506 binding
protein (calstabin)
GAS = gastrocnemius
HADHA = hydroxyacyl-CoA
dehydrogenase/3-ketoacyl-CoA
thiolase/enoyl-CoA hydratase
HMG CoA = 3-hydroxy-3-
methylglutaryl coenzyme A
L-NAME = N(u)-nitro-L-
arginine methyl ester
NOS = nitric oxide synthase
PGC1a = peroxisome
proliferator-activated receptor
g co-activator 1a
RNS = reactive nitrogen
species
ROS = reactive oxygen species
RyR = ryanodine receptor
SOD = superoxide dismutase
SR = sarcoplasmic reticulum
TUNEL = terminal
deoxynucleotidyl transferase
dUTP nick end labeling
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510SUMMARYThis study aimed to identify a mechanism for statin-induced myopathy that explains its prevalence and
selectivity for skeletal muscle, and to understand its interaction with moderate exercise. Statin-associated
adverse muscle symptoms reduce adherence to statin therapy; this limits the effectiveness of statins in
reducing cardiovascular risk. The issue is further compounded by perceived interactions between statin treat-
ment and exercise. This study examined muscles from individuals taking statins and rats treated with statins for
4 weeks. In skeletal muscle, statin treatment caused dissociation of the stabilizing protein FK506 binding
protein (FKBP12) from the sarcoplasmic reticulum (SR) calcium (Ca2þ) release channel, the ryanodine receptor 1,
which was associated with pro-apoptotic signaling and reactive nitrogen species/reactive oxygen species (RNS/
ROS)dependent spontaneous SR Ca2þ release events (Ca2þ sparks). Statin treatment had no effect on Ca2þ
spark frequency in cardiac myocytes. Despite potentially deleterious effects of statins on skeletal muscle, there
was no impact on force production or SR Ca2þ release in electrically stimulated muscle ﬁbers. Statin-treated
rats with access to a running wheel ran further than control rats; this exercise normalized FKBP12 binding to
ryanodine receptor 1, preventing the increase in Ca2þ sparks and pro-apoptotic signaling. Statin-mediated RNS/
ROSdependent destabilization of SR Ca2þ handling has the potential to initiate skeletal (but not cardiac)
myopathy in susceptible individuals. Importantly, although exercise increases RNS/ROS, it did not trigger
deleterious statin effects on skeletal muscle. Indeed, our results indicate that moderate exercise might beneﬁt
individuals who take statins. (J Am Coll Cardiol Basic Trans Science 2019;4:509–23) © 2019 The Authors.
Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).S tatins are the most widely prescribeddrug in the Western world. Their useis predicted to rise further due to
recent reductions in the cardiovascular risk threshold
for statin prescription across the globe (1,2). However,
cardiovascular beneﬁts of statins are restricted by
adverse effects that limit adherence (3,4) and, in
turn, increase cardiovascular events (5) and mortality
(6). The most common side effects and main reason
for discontinuation of therapy emerge from skeletal
muscle (statin myopathy or statin-associated adverse
muscle symptoms). Although no strict deﬁnition of
statin myopathy has been universally adopted
(7–10), we use this term to encompass the full spec-
trum of the effects of statins on skeletal muscle.SEE PAGE 524This includes mild to moderate muscle symptoms
and/or signs (myalgia: muscle pain with stiffness
and weakness), as well as more severe potentially
life-threatening outcomes (myositis and/or rhabdo-
myolysis) that are associated with raised creatine
kinase (8,11). Although physical activity counteracts
metabolic and cardiovascular diseases that are preva-
lent in subjects prescribed statins, exercise has been
reported to exacerbate statin myopathy (12–19),
which may further limit the beneﬁts of statins in
those at risk of cardiovascular disease.
Statins are inhibitors of 3-hydroxy-3-methylglutaryl
coenzyme A (HMG CoA) reductase that limit theproduction of cholesterol, isoprenoids, and coenzyme
Q. Despite extensive research, which has focused on
calcium (Ca2þ) homeostasis and mitochondrial func-
tion (20–25), a cohesive mechanism for statin-induced
myopathy is lacking. Furthermore, an understanding
of why myopathy is not experienced by everyone who
takes statins and the reason for its selectivity for
skeletal muscle has not been fully addressed.
Using human and rodent muscle, we investigated
the mechanism for statin-induced myopathy and
described its interaction with voluntary moderate ex-
ercise. We revealed a mechanism by which statin
treatment can make skeletal muscles susceptible to
myopathy—dissociation of the FK506 binding protein
(FKBP12) from the sarcoplasmic reticulum (SR) Ca2þ
release channel, the ryanodine receptor 1 (RyR1),
which is accompanied by numerous spontaneous Ca2þ
release events (i.e., Ca2þ sparks) (26). Statin treatment
had no effect on Ca2þ sparks in cardiac muscle. Aber-
rant SR Ca2þ handling was associated with pro-
apoptotic signaling in skeletal muscle. However,
despite this myopathy-promoting signaling, statin
treatment had no obvious detrimental effect on the
contractile function of skeletal muscle, which suggests
that additional factors are required to produce
myopathic symptoms. Furthermore, in rats that un-
derwent voluntary exercise, no overt muscle
dysfunction was evident. Our data demonstrate that
individuals taking statinsmight beneﬁt frommoderate
exercise.
TABLE 1 Patient Data
Statin
Statin Matched Control Subjects
Dose
(mg) Sex
Age
(yrs) Histology
CK
(IU/l) Disease
Age
(yrs) Histology
CK
(IU/l) Disease
SIMV 40 F 48 Type 2b ﬁber atrophy HC, H 47 Normal Treated
hypothyroidism
SIMV 40 M 72 Type 2b ﬁber atrophy RM 73 Type 2b ﬁber atrophy 110 H, DM, minor CVA
SIMV 20 M 65 Fiber size, variation,
increase in mitochondria
76 H, RM 65 Type 2b ﬁber atrophy 200
SIMV 40 F 60 Normal Type 2 DM, CVA, obese 60 Normal 110
SIMV 40 M 70 Normal H, AA 70 Normal 142 H
SIMV 10 M 71 122 H 71 Fiber size variation H, CVA
SIMV 40 M 48 Normal 157 H 48
PRAV 30 M 58 Atrophy in scattered ﬁbers H 58 Normal 102
SIMV 20 M 72 Atrophy and angulation
in many ﬁbers
116 H 71 Normal 138 MV
SIMV 40 M 59 Type 2 DM, CVA, obese 59 Normal 97
ATOR 20 M 56 IHD 56 Normal H
ROSU 10 F 54 Normal 114 H 54
SIMV 20 F 52 Normal 57 H 51 Normal
All samples from patients taking statins were paired with sex- and age-matched control subjects. Details of histology, serum creatine kinase (CK), and disease are given where available.
AA¼ aortic aneurysm; CVA ¼ cerebrovascular accident; DM¼ diabetes mellitus; H ¼ hypertension; HC ¼ high cholesterol; IHD¼ ischemic heart disease; MV¼mitral valve disease; RM ¼ risk
modiﬁcation.
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511METHODS
STUDY APPROVAL. Anonymized vastus medialis
samples were obtained from patients who were
screened (and tested negative) for malignant hy-
perthermia. Individuals taking statins were age- and
sex-matched with control subjects (Table 1). All pa-
tients gave informed consent. This study complied
with the principles of the Declaration of Helsinki
and was approved by the Leeds East Local Research
Ethics Committee. Work with rodents was per-
formed in strict accordance with the recommenda-
tions of the Directive 2010/63/EU of the European
Parliament and was approved by animal welfare
committees at the University of Leeds and the
Karolinska Institutet.
RODENT MODELS. Male Wistar rats (130 to 160 g)
received simvastatin (40 mg/kg/day) or saline by
oral gavage at the beginning of the dark cycle for
28 days (see Supplemental Methods for justiﬁcation
of dose). For exercise studies, rats were given free
access to an in-cage running wheel. Custom-built
hardware and software allowed detailed character-
istics of running activity to be recorded for each
animal (see Supplemental Methods). All animals
were killed by stunning and cervical dislocation.
RODENT MUSCLE PREPARATIONS. For protein
chemistry, rat gastrocnemius (GAS) muscle (a pre-
dominantly type II muscle) was dissected to remove
slow oxidative type I ﬁbers (dark red in color). Forconfocal microscopy, rat ﬂexor digitorum brevis
(FDB) ﬁbers were isolated by collagenase digestion
(27). FDB is predominantly type IIa; the choice of
this muscle was informed by the short length of the
ﬁbers that allows the isolation and study of intact
cells. In some cases, ﬁbers were permeabilized by 2-
min exposure to 0.005% (w/v) saponin (28). Rat
cardiac myocytes were isolated from Langendorff-
perfused hearts by collagenase and protease diges-
tion (29).
MUSCLE FUNCTION IN VITRO. Rat single FDB ﬁbers
were dissected, mounted, and electrically stimulated
via platinum plates. The isolated muscle preparations
were stimulated for 350 ms at 10 to 150 Hz at 1-min
intervals, and the resultant force was measured. The
ﬂuorescent Ca2þ indicator indo-1 was pressure injec-
ted into ﬁbers, and the ﬂuorescence signals of indo-1
were recorded at rest and during contractions as
described previously (30).
CONFOCAL MICROSCOPY. Confocal images were ac-
quired with a Eclipse TE300 inverted microscope
(Nikon, Minato, Tokyo, Japan) equipped with a
confocal scanhead, MicroRadiance 2000 (Bio-Rad,
Hercules, California), and a 60 water-immersion
objective. FDB ﬁbers were loaded with ﬂuo 4-AM
(5 mM, for intact cells), ﬂuo 3 (50 mM, for per-
meabilized cells), or DAF-2 (5 mM). Cardiac myocytes
were loaded with ﬂuo 4-AM (6 mM). Dyes were excited
with the 488-nm line of a 20-mW coherent sapphire
laser (attenuated z90%), and emitted ﬂuorescence
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512was measured at >515 nm. Images were acquired in
x-y (every 5 s) or line scan mode (every 6 ms). Ca2þ
sparks were identiﬁed and analyzed with ImageJ
software version 1.51j8, National Institutes of Health,
Bethesda, Maryland) using the Sparkmaster plugin
(see Supplemental Methods).
PROTEIN CHEMISTRY AND ASSAYS. Sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and
Western blotting were carried out as described
in Calaghan et al. (29). Data were normalized
to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) expression. Because it was not possible to
load all samples on the same gel, a standard calibra-
tion sample (mixed from 4 human vastus medialis
samples or 3 rat GAS samples) was loaded in duplicate
on gels to allow between-gel comparisons. For RyR
post-translational modiﬁcations and protein associa-
tions, RyR1 was immunoprecipitated from GAS as
described previously (31) (see Supplemental
Methods). The terminal deoxynucleotidyl trans-
ferase dUTP nick end labeling (TUNEL) assay was
performed on cryostat sections (10 mm; Leica CM
1900), visualized using the detection kit TACS 2TdT-
DAB for In situ Apoptosis (4810-30-K, Trevigen) (32).
Calpain activity was assessed using the assay kit
QIA120 (Merck Millipore).
ANTIBODIES. Antibodies were as follows: calmod-
ulin Abcam Cat# ab45689 RRID:AB_725815, 1:1,000;
FKBP12 Abcam Cat# ab58072 RRID:AB_941602, 1:200;
hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA
thiolase/enoyl-CoA hydratase (HADHA) Abcam Cat#
RRID:AB_2263836 1:1,000; peroxisome proliferator-
activated receptor g co-activator 1a (PGC1a) Abcam
Cat# ab54481 RRID:AB_881987, 1:1,000; RyR clone
34C Abcam Cat# ab2868 RRID:AB_2183051, 1:5,000;
Cav 3 BD Biosciences Cat# 610420 RRID:AB_397800,
1:5000; endothelial nitric oxygen synthase eNOS BD
Biosciences Cat# 610297 RRID:AB_397691, 1:2,500;
Cav 1 Boster Biological Technology Cat# PA1514,
RRID: AB_2651038, 1:1,000; caspase-3 Cell Signaling
Technology Cat# 9665 also 9665S RRID:AB_2069872,
1:1000; nNOS Cell Signaling Technology Cat# 4231S
RRID:AB_2152485, 1:1,000; and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) Sigma-Aldrich
Cat# G9545 RRID:AB_796208, 1:100,000.
STATISTICAL ANALYSIS. Results are expressed as
mean  SEM of number of observations, with p < 0.05
used to denote statistical signiﬁcance. The Shapiro-
Wilk test was used to test for normality. For the hu-
man study, we had access to 13 samples from statin-
treated individuals and 13 age- and sex-matched
control subjects. The paired Student’s t-test (nor-
mally distributed data) or the Wilcoxon signed-ranktest (non-normally distributed data) were used to
compare groups. This sample size gave power >0.8 to
detect a 100% change in parameter (SD: 100% of
mean; paired Student’s t-test). For rodent samples,
comparison of 2 groups was performed using the
Student’s t-test (normal distribution) and the Mann-
Whitney rank test (non-normal distribution). For
tetanic and force Ca2þ measurements at different
frequencies of stimulation, a 2-way repeated mea-
sures analysis of variance was used (with the Holm-
Sidak post hoc test). Two-way analysis of variance
(with the Tukey post hoc test) was used to analyze
daily running distance with time in the control and
statin groups, and the effect of exercise and statin
treatment on markers of mitochondrial biogenesis.
For rodent studies, we used 10/11 and 5/6 animals in
the sedentary control/statin groups in the United
Kingdom and Sweden (tetanic force and Ca2þ mea-
surements), respectively. For the exercise study, we
used 6/6 control/statin-treated animals. Group sizes
were based on power calculations for protein chem-
istry data from the rat, which showed power >0.8 to
detect a 50% difference in means when n ¼ 6 (SD: 25%
of mean; t-test). Presented data might have different
numbers of animals for some endpoints due to
sample limitations. GraphPad Prism (version 7.05,
Graphpad, San Diego, California) was used for all
statistical analysis, with the exception of tetanic
force and Ca2þ measurements (Sigmaplot for
Windows, version 13.0, Systat Software Inc., San
Jose, California).
RESULTS
SUMMARY OF EXPERIMENTAL PLAN AND KEY
FINDINGS. Supplemental Table 1 provides a sum-
mary of all experiments performed, with key ﬁndings
for both human and rodent preparations.
DISSOCIATION OF FKBP12 FROM RyR1 AND
PRO-APOPTOTIC SIGNALING IN SKELETAL MUSCLE
OF STATIN-TREATED HUMANS AND RATS. Post-
translational modiﬁcations of RyR1 and changes in the
molecular composition of the RyR1 protein complex
are present in several conditions with dysfunctional
skeletal muscle (33–35). To test whether similar alter-
ations occurred with statin treatment, we immuno-
precipitated RyR1 in homogenates prepared from
biopsies of human vastus medialis muscles and from
isolated rat GAS muscles, and measured the expres-
sion of the RyR1 binding partners FK506 binding pro-
tein 12 (FKBP12) and calmodulin. Statin treatment
caused a marked decrease in FKBP12 bound to RyR1 in
both human and rat muscle, whereas the calmodulin
binding remained intact (Figures 1A and 1B). It was
FIGURE 1 Dissociation of FKBP12 From RyR1 and Pro-Apoptotic Signaling in Skeletal Muscle From Statin-Treated Humans and Rats
Representative blots from the same gel and mean data showing FK506 binding protein (FKBP12) and calmodulin (CaM) in ryanodine receptor (RyR) immunoprecipitates
from (A) human and (B) rat muscle. All values are standardized to the mean of the control group. There was no difference (p > 0.05) in total RyR1 or FKBP12
expression between groups. Data from 11/11 (FKBP) and 13/13 (CaM) patients taking statins (S) and age- and sex-matched controls (C); n ¼ 10 to 11 rats.
(C) Representative blots from the same gel and mean data from human muscle showing pro-caspase 3 (pro-cas3; 35 kDa) and cleaved caspase 3 (cas3; 17 kDa). Data
from 13/13 patients. (D) Expression of pro-cas3, cleaved cas3 and (E) proportion of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) positive
nuclei (%) in rat muscle. Cas3 expression is standardized to the mean of the control group. Data from 5 to 7 animals. All data are mean þ SEM. (A) *p ¼ 0.0127 (paired
Student’s t-test). (B) **p ¼ 0.0023 (Student’s t-test). (C) *p ¼ 0.0425 (Wilcoxon signed-rank test). (D) *p ¼ 0.0158 (Student’s t-test); ****p < 0.0001 (Student’s
t-test). GADPH ¼ glyceraldehyde-3-phosphate dehydrogenase.
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513noteworthy that a robust dissociation of FKBP12
from RyR1 could be detected, although muscle
biopsies were obtained from a diverse patient
group (Table 1).
FKBP12 dissociation from RyR1 has been shown to
increase spontaneous SR Ca2þ leak, which, in turn,
promotes protein degradation and programmed cell
death (33). Therefore, we next studied whether the
change in the RyR complex in muscles of statin-
treated subjects was accompanied by indexes of
pro-apoptotic signaling. For this purpose, we
measured the protein expression of the inactive pro-
caspase-3 and its cleaved active product, the pro-
apoptotic enzyme caspase-3. Statin treatment
increased caspase-3 expression in both human and rat
muscles (Figures 1C and 1D). In rat muscle, we also
measured the proportion of TUNEL positive nuclei,
which is another marker for pro-apoptotic signaling,
and observed a marked increase with statin treatment
(Figure 1E). Thus, muscles from both humans and rats
treated with statins showed major alterations that
were potentially deleterious and might underliestatin-induced myopathy. In subsequent experi-
ments, we delved deeper into mechanisms of the
statin-induced effects; these experiments were only
performed on rat muscles due to limitations in what
can be performed on human muscle biopsy material.
STATIN TREATMENT INCREASES SR Ca2D LEAK IN
INTACT SKELETAL MUSCLE. SR Ca2þ leak in the form
of Ca2þ sparks (elementary Ca2þ release events from
clusters of RyR1) is a myopathic mechanism common
to many skeletal muscle diseases, including muscular
dystrophy and malignant hyperthermia (33,36).
Although spark-mediated SR Ca2þ leak is an attractive
culprit for statin-induced myopathy, no overt
changes in Ca2þ spark characteristics with (in vivo)
statin treatment have been documented to date
(20,21,23). However, all previous work has been per-
formed on permeabilized muscle ﬁbers, in which the
constitutive inhibition of RyR1 by magnesium (37)
and the dihydropyridine receptor (38) is reduced,
which may mask the effects of statins. Therefore, we
evaluated the effect of statin treatment on the SR
FIGURE 2 Statin Treatment Provokes SR Ca2þ Leak in Skeletal, But Not Cardiac, Myocytes
Representative confocal line scans (F/F0) with associated line proﬁles and mean data from (A to C) intact ﬂexor digitorum brevis (FDB) ﬁbers and (D to F) cardiac
myocytes; n ¼ 11/10 (FDB) and 5/5 (cardiac myocytes) rats for control/statin-treated groups, number of cells shown on graphs. Data are mean þ SEM and compared
using the Mann-Whitney rank test. (C) ****p < 0.0001; *p ¼ 0.0307; **p ¼ 0.0029 (mass); **p ¼ 0.0091 (leak). (F) **p ¼ 0.0024. Ca2þ ¼ calcium; FWHM ¼ full width
at half maximum; SR ¼ sarcoplasmic reticulum.
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514Ca2þ leak in intact muscle ﬁbers. Ca2þ sparks were
recorded in nonpermeabilized ﬂuo 4-loaded FDB ﬁ-
bers from the rat (Figures 2A to 2C). As predicted (39),
spark frequency was low in intact ﬁbers from control
animals. In marked contrast, in ﬁbers from statin-
treated rats, sparks were much more frequent, of
longer duration, and larger in amplitude, which
resulted in an increased spark mass and spark-
mediated Ca2þ leak. Interestingly, this robust effect
of statins on spark characteristics was lost following
ﬁber permeabilization (Supplemental Figure S1),
which explains discrepancies with previous work
(20,21,23) and suggests that statin effects in intact
cells depend on the normal regulation of the RyR1
and/or effects of a soluble mediator.
An important question is whether statin-induced
SR Ca2þ leak is also seen in cardiac muscle because
this could have additional detrimental consequences
by promoting triggered arrhythmias (40). Reassur-
ingly, there was minimal impact of statin treatment
on Ca2þ sparks in intact cardiac myocytes from statin-
treated rats (Figures 2D to 2F). Thus, statin treatmentinduces SR Ca2þ leak in skeletal muscle, whereas
cardiac muscle is protected from this potentially
deleterious effect.
NOS AND REACTIVE OXYGEN SPECIES PROMOTE SR
Ca2D LEAK WITH STATIN TREATMENT. Reactive ni-
trogen species and reactive oxygen species (RNS/
ROS) could account for the statin-induced SR Ca2þ
leak; both can be increased by statin treatment
(25,41,42), target the RyR and its associated proteins
directly (43,44) and indirectly (45), and affect RyR
activity (46). Inhibition of NOS isoforms with N(u)-
nitro-L-arginine methyl ester (L-NAME) had a
greater impact on NO (indexed with DAF-2) in FDB
ﬁbers from statin-treated rats than in control rats,
which was consistent with higher NOS activity in the
statin group (Figure 3A). This could be explained by
increased expression of endothelial NOS and
reduced expression of the NOS-inhibitory caveolin
isoform Cav1 (Figure 3B). These observations were
consistent with statins acting as inhibitors of HMG
CoA reductase and established pathways in which
FIGURE 3 Nitric Oxide Synthase and Reactive Oxygen Species Promote SR Ca2þ Leak With Statin Treatment
(A) Representative traces and mean data showing the impact of N(u)-nitro-L-arginine methyl ester (L-NAME) (1 mM) on DAF-2 ﬂuorescence in FDB ﬁbers. Within
each cell, the rate of increase in DAF-2 ﬂuorescence recorded before L-NAME was subtracted from the entire trace; n ¼ 7/8 animals for control/statin-treated
rats, number of cells shown on graph. (B) Representative blots from the same gel and mean data from rat gastrocnemius (n ¼ 9 to 11 animals). Ca2þ spark
frequency and duration in intact FDB ﬁbers in the presence of (C) L-NAME (1 mM), (D) Mn (III)tetrakis(1-methyl-4-pyridyl)porphyrin (MnTMPyP) (0.1 mM), and
(E) (2-(2,2,6,6-Tetramethylpiperidin-1-oxyl-4-ylamino)-2-oxoethyl)triphenylphosphonium chloride (mitoTEMPO) (25 mM); n ¼ 3 animals, number of cells
shown on graphs. (F) The impact of the mitochondrial Ca2þ uniporter inhibitor Ru360 (20 mM, 15 min) in intact FDB ﬁbers on increased Ca2þ spark frequency and
duration. Data from 7 animals (number of cells shown on graph). All data are mean þ SEM and compared using Mann-Whitney rank test. (A) * p ¼ 0.034.
(B) ** p ¼ 0.0042 (endothelial nitric oxygen synthase [eNOS]), **p ¼ 0.0073 (caveolin 1 [Cav1]); other abbreviations as in Figures 1 and 2.
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515products of the HMG CoA reductase cascade regulate
NOS (isoprenoids) and caveolin (cholesterol)
expression (47). Enhanced NOS activity was directly
linked with Ca2þ leak because, in the presence of L-
NAME, there was no longer any difference (p > 0.05)
in Ca2þ spark frequency or duration between ﬁbers
from control and statin-treated rats (Figure 3C).
L-NAME inhibits NO and superoxide production from
NOS (48), which indicates a role for NO, superoxide,
and/or peroxynitrite in the spark-mediated leak.
Statin treatment has been shown to increase ROS
production in skeletal muscle (25). We showed
that these ROS played a role in the SR Ca2þ leak,
because the superoxide dismutase (SOD) and perox-
ynitrite scavenger Mn(III)tetrakis(1-methyl-4-pyridyl)
porphyrin (MnTMPyP) and themitochondrial-targeted
SOD mimetic (2-(2,2,6,6-Tetramethylpiperidin-1-oxyl-4-ylamino)-2-oxoethyl)triphenylphosphonium chlo-
ride (mitoTEMPO) eliminated the difference (p > 0.05)
in Ca2þ spark frequency and duration between ﬁbers
from control and statin-treated rats (Figures 3D and 3E).
Bidirectional Ca2þ ﬂuxes between SR and mito-
chondria affect both SR and mitochondrial function.
Mitochondria accumulate close to SR Ca2þ release
sites during postnatal skeletal muscle maturation,
which facilitates mitochondrial Ca2þ uptake and
is associated with reduced susceptibility to Ca2þ
spark activation (49). Conversely, excessive mito-
chondrial Ca2þ uptake may promote Ca2þ sparks by
enhancing ROS production from complexes I and III
(50,51). In support of this latter mechanism, the
difference in Ca2þ spark frequency and duration
between ﬁbers from control and statin-treated rats
was no longer present after inhibiting Ca2þ entry
FIGURE 4 Impact of Statin Treatment on Basal and Tetanic [Ca2þ]i and Force Production
Representative [Ca2þ]i transients at (A) 30 Hz and (C) 100 Hz, and (E) mean data for 10 to 150 Hz in FDB ﬁbers stimulated with 350 ms trains
of pulses at 1-min intervals. Corresponding representative force records at (B) 30 Hz and (D) 100 Hz, and (F) mean data for 10 to 150 Hz.
From n ¼ 13/11 ﬁbers from 5/6 animals for control/statin-treated animals. Data are mean  SEM and compared with 2-way repeated-measures
analysis of variance. (F) *p ¼ 0.020 (15 Hz); p ¼ 0.003 (20 Hz); p ¼ 0.005 (30 Hz); p ¼ 0.042 (40 Hz) versus control subjects. Abbreviations
as in Figure 2.
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516into the mitochondria via the mitochondrial Ca2þ
uniporter with Ru360 (52) (Figure 3F). Taken
together, the impact of NOS inhibition with
L-NAME, ROS scavengers, and mitochondrial Ca2þuniporter inhibition suggests that mitochondrial
Ca2þ uptake stimulates RNS/ROS production, which,
in turn, acts on RyR1 to maintain and/or exacerbate
the SR Ca2þ leak.
FIGURE 5 Statin Treatment Increases Physical Activity
Running wheel data from the dark cycle (active period). Rats were acclimatized to the wheel for 4 days before statin treatment commenced (day 0). (A) Daily running
distance over the duration of the study. (B to D) Detailed analysis of activity for the 28-day treatment period. Bouts (continuous periods of activity) were deﬁned as
activity seen in $2 consecutive minutes. Pulse velocity represents the mean velocity of each one-quarter revolution (pulse) of the wheel. Data are mean  SEM
(n ¼ 6 animals per group). (A) ####p < 0.0001 for statin effect (2-way analysis of variance). (B) *p ¼ 0.0148 versus control (t-test).
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517CONSEQUENCES OF STATIN-INDUCED SR Ca2D
LEAK FOR MUSCLE FUNCTION. Next, we determined
whether the observed effects of statins had a net
impact on muscle function by measuring the free
cytosolic [Ca2þ] ([Ca2þ]i) and force production in
electrically stimulated single FDB ﬁbers (30). There
was no signiﬁcant difference in basal [Ca2þ]i (69  5
nM vs. 72  3 nM; n ¼ 13/11) or tetanic [Ca2þ]i
(Figures 4A, 4C, and 4E) between FDB ﬁbers from
control and statin-treated animals. Furthermore,
statin treatment did not reduce force production at
any frequency; at low-frequency stimulation
(#40 Hz) there was a small increase in tetanic force in
the statin group (Figures 4B and 4F). Calpains belong
to a family of Ca2þ-dependent proteolytic enzymes
with pro-apoptotic activity (53). Calpain activity did
not differ between control and statin-treated muscle
(9.3  0.4 vs. 9.3  0.2 AU; n ¼ 10), which was
consistent with the unaltered basal [Ca2þ]i. Thus, in
resting muscle, the statin-induced SR Ca2þ leak was
effectively counteracted by alterations in SR Ca2þ
uptake and/or Ca2þ ﬂuxes across the cell membrane
(54). This concept of compensated leak was proposed
to explain normal basal [Ca2þ]i in conjunction with
Ca2þ leak from RyR1 due to a mutation found in ma-
lignant hyperthermia (Y522S) (36). During contrac-
tions, the amount of Ca2þ released in response to
action potential stimulation remains constant over a
wide range of SR Ca2þ content in fast-twitch muscle
ﬁbers (55), and depletion of SR Ca2þ promotes reﬁlling
via store-operated Ca2þ entry (56). Thus, the unaf-
fected tetanic [Ca2þ]i in muscle ﬁbers from statin-
treated rats was also compatible with the observed
spark-mediated SR Ca2þ leak in these ﬁbers.MODERATE EXERCISE REVERSES THE IMPACT OF
STATINS ON SKELETAL MUSCLE. Exercise is recom-
mended for those at risk of cardiovascular disease
(i.e., those who take statins). However, there are re-
ports that exercise reveals or exacerbates statin
myalgia (13,14) and myositis (12,15,16), and that sta-
tins limit training adaptations in skeletal muscle
(57,58). Therefore, we gave statin-treated and control
rats access to an in-cage running wheel, which
resulted in a type of voluntary exercise similar to that
recommended for human subjects prescribed statins.
Rats were acclimatized to the wheel for 4 days before
statin treatment commenced. Unexpectedly, the
daily running distance was greater for statin-treated
rats than for control rats across the 4 weeks of the
study (Figure 5A). The larger daily running distance in
the statin group was due to an increase in the number
of bouts of activity (Figure 5B), whereas the running
bout duration (Figure 5C) and running velocity
(Figure 5D) were similar in the 2 groups.
In sharp contrast to the situation in muscles of
sedentary subjects (see Figure 1), binding of FKBP12 to
RyR1 showed no signiﬁcant difference between
muscles of statin-treated and control rats after
4 weeks of exercise (Figures 6A and 6B). Moreover, in
the exercised state, statin treatment no longer caused
a signiﬁcant increase in caspase 3 expression
(Figures 6C and 6D). Intriguingly, in the exercised
state, the frequency of SR Ca2þ sparks was lower in
muscle ﬁbers of statin-treated rats than in control
rats, which contributed to a smaller spark-mediated
Ca2þ leak in this group (Figures 6E to 6G).
A number of studies have linked statin-induced
myopathy with impaired mitochondrial biogenesis.
FIGURE 6 Exercise Reverses the Effect of Statin Treatment on the RyR Complex, Apoptosis, and SR Ca2þ Leak
(A) Representative blots and (B)mean data of FKBP12 and CaM in RyR immunoprecipitates from gastrocnemius muscle of exercised animals. Data are normalized to RyR
and standardized to the mean of the control exercise group (n¼ 6 animals). C¼ control, S¼ statin. (C) Representative blots and (D)mean data of pro-cas 3 and cleaved
cas 3 expression in gastrocnemius homogenates of exercised animals. Data are normalized to GAPDH and standardized to the mean of the control exercise group (n ¼ 6
animals). (E) Mean data for spark frequency, duration, and spark-mediated leak in intact FDB ﬁbers from n ¼ 6 exercised animals per group, number of cells shown on
graph. Data are mean þ SEM and compared using the (B) Student’s t-test and (D to G) Mann-Whitney. *p ¼ 0.0197; **p ¼ 0.0061. Abbreviations as in Figures 1 to 3.
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518The transcriptional co-activator PGC1 is a key medi-
ator of mitochondrial biogenesis in response to
endurance exercise (59–61). Statin treatment has been
shown to decrease PGC1a mRNA expression in human
and rodent fast skeletal muscle (24); however, no
change in PGC1a protein was detected in rodent
muscle (62). We saw no impact of statin treatment on
protein expression of PGC1a or HADHA (which is used
as an index of mitochondrial biogenesis) either in
sedentary or exercised animals (Figures 7A to 7C).Together, these data show that statin treatment did
not limit moderate physical activity or markers of
training adaptation in skeletal muscle. Exercise
reversed the statin-dependent SR Ca2þ leak, which
suggests a potentially beneﬁcial effect.
DISCUSSION
The prevalence of statin-induced muscle symptoms
varies between 7% and 29% in registries and
FIGURE 7 Statins Do Not Limit Mitochondrial Biogenesis in Sedentary or Exercised Rats
(A) Representative blots and (B and C) mean data from rat gastrocnemius homogenates showing peroxisome proliferator-activated receptor g co-activator 1a (PGC1a)
and hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (HADHA) expression. Mean data are normalized to GAPDH. Data are mean þ SEM
from 6 to 11 animals. (B) **p ¼ 0.0034 versus sedentary control animals; ##p ¼ 0.0034 between groups as indicated. (C) ****p < 0.0001 versus sedentary control
animals; ##p ¼ 0.0025; ###p ¼ 0.0001 between groups as indicated (2-way analysis of variance with Tukey test for post hoc analysis). Abbreviation as in Figure 1.
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519observational studies (63). Thus, most patients taking
statins do not experience skeletal muscle problems.
In skeletal muscle of statin-treated humans and rats,
we showed FKBP12 dissociation from RyR1, which
resulted in a ROS/RNSdependent Ca2þ spark-
mediated SR Ca2þ leak. Such destabilization of RyR1
has been associated with muscle dysfunction in a
variety of conditions, including heart failure, aging,
and muscular dystrophy (33–35). Accordingly, we
observed indexes of pro-apoptotic signaling in statin-
treated subjects. Nevertheless, in the rodent model,
statin-induced FKBP12 dissociation from RyR1 and
Ca2þ sparks were not accompanied by any obvious
defects in the overall control of [Ca2þ]i at rest or
during tetanic stimulation, and force production was
not decreased. Unaltered muscle function, despite
potentially deleterious changes in cellular Ca2þ
handling, ﬁts with the clinical picture that although
statin treatment increases the risk of myopathy, most
patients do not experience statin-associated adverse
muscle symptoms. Indeed, analysis of mitochondrial
DNA and muscle gene expression proﬁles in a small
group of patients taking simvastatin for 8 weeks
revealed evidence of mitochondrial damage, pro-
apoptotic signaling, and altered Ca2þ ﬂux despite an
absence of muscle symptoms (64). Thus, we argue
that statin treatment initiates potentially detrimental
changes in skeletal muscle as a result of Ca2þ dysre-
gulation, but that this does not usually translate into
myalgia or more serious muscle derangement.
CARDIAC MUSCLE IS PROTECTED FROM
STATIN-INDUCED MYOPATHY. In contrast to skeletal
muscle, we observed no increase in spark-mediatedSR Ca2þ leak in cardiac myocytes from statin-treated
rats. Our results showed a central role of increased
ROS/RNS in the statin-induced destabilization of SR
Ca2þ control. This offers a simple explanation for the
selectivity of statins for skeletal muscle: cardiac
muscle has superior enzymatic (e.g., SOD) and
nonenzymatic (e.g., glutathione) ROS/RNS defense
systems to fast skeletal muscle (24,25). Furthermore,
statin treatment has been shown to enhance the
antioxidant defense in cardiac muscle while limiting
the defense in skeletal muscle (24). In addition, direct
effects of the statin molecule on RyR might also
contribute to selective skeletal myopathy. In planar
lipid bilayers, simvastatin increases the open proba-
bility of RyR1 but not RyR2 (28). Similarly, acute
application of simvastatin to permeabilized cells
shifts the distribution of Ca2þ spark frequency toward
higher values in skeletal ﬁbers (which express pre-
dominantly RyR1) but lower values in cardiac myo-
cytes (which express RyR2) (28). Thus, a central role
for RyR in statin myopathy fully explains the selec-
tivity of this effect for skeletal over cardiac muscle.
MODERATE EXERCISE MAY LIMIT DETERIMENTAL
EFFECTS OF STATINS ON SKELETAL MUSCLE. The
prevalence of statin-induced myopathy has been re-
ported to increase with physical activity in rodent
models (16) and in humans (12,15). RNS/ROS increase
during exercise and strenuous skeletal muscle activ-
ity can result in severe FKBP12 dissociation from RyR1
and impaired contractile function (65,66), thus
providing a mechanism by which exercise could
exaggerate the negative effects of statin treatment. In
contrast, increased RNS/ROS and altered SR Ca2þ
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520handling play an important role in the adaptation to
endurance training (67–70), and a moderate SR Ca2þ
leak has been linked to increased fatigue resistance
(71,72). We showed beneﬁcial effects of voluntary
running exercise in muscle of statin-treated rats.
Statin treatment no longer reduced FKBP12 binding to
RyR1, increased caspase 3 expression, or increased
Ca2þ spark frequency. Measures of mitochondrial
biogenesis (PGC1a and HADHA expression) were
enhanced, at least to the same extent, as in muscle of
trained control rats. Thus, our results imply that
combining moderate voluntary exercise with statin
treatment is not detrimental and might limit poten-
tially harmful muscle effects of statins. Of note, most
reports of exacerbation of statin myopathy are with
intense, prolonged, or enforced exercise regimens
(12,15,16). Data from the PRIMO study (73) hinted at
the relationship between exercise intensity and the
incidence of statin-associated muscle symptoms, and
it was recently suggested that reducing the intensity
of exercise could mitigate the myopathy risk (18). The
opposing intensity-dependent effects of exercise
likely reﬂect a narrow span between limited FKBP12
dissociation from RyR1 accompanied by improved
muscle endurance (71,72) and severe FKBP12 dissoci-
ation resembling ‘overtraining’ with marked muscle
weakness (65,66).
Unexpectedly, statin-treated rats performed more
bouts of activity per day, which translated into longer
distances run, compared with control rats. This
ﬁnding seemingly excluded statin-induced muscle
pain or other sensory-related symptoms, because
such symptoms were unlikely to result in an
increased willingness to perform voluntary exercise.
The increased voluntary running of statin-treated rats
might relate to their increased muscular NO produc-
tion, because mice given dietary nitrate supplemen-
tation run more than control mice (74).
STUDY LIMITATIONS AND SIGNIFICANCE. A limita-
tion of the present study is that although we identi-
ﬁed a potentially harmful effect of statin treatment,
we did not provide direct evidence of conditions in
which the increased SR Ca2þ leak resulted in
myopathic symptoms. The likely scenario is that the
statin-induced RyR1 destabilization has to be com-
bined with other factor(s) for myopathic symptoms to
occur. The concept that individuals might be geneti-
cally predisposed to myopathy as a result of altered
statin metabolism and/or muscle susceptibility is
gaining acceptance (75–77). There is strong support
for dysregulation of Ca2þ handling contributing to
muscle susceptibility. For example, disease-causingmutations or rare variants in RyR1 have been found
in those who experienced statin-associated muscle
symptoms (78). Nearly one-ﬁfth of a cohort of sub-
jects who had severe statin myositis had rare variants
within genes for RyR1 and the pore-forming subunit
of the L-type Ca2þ channel (76). Gene expression
analysis of muscle from patients with a history of
statin myalgia who were re-challenged with statins
revealed a number of pathways and networks linked
with RyR regulatory proteins, including calmodulin
and autocrine motility factor (which plays a role
in endoplasmic reticulum (ER)/SR-mitochondrial
communication) (79), and regulatory Ca2þ-binding
proteins (calpain, calcineurin) (75). Accordingly, in a
study on patients with statin-induced myositis, most
(7 of 9) of the in vitro muscle tests showed halothane-
and caffeine-induced contractures suggestive of
impaired SR Ca2þ control and, in 1 patient, the ab-
normality was consistent with malignant hyperther-
mia, a disorder linked to variants in RYR1 (80).
Moreover, lifestyle habits, such as excessive exercise
regimens that induce SR Ca2þ leak via RyR1 FKBP12
dissociation, might also reveal overt myopathy with
statin treatment as discussed above.
We only studied rats treated with statins for
4 weeks, and it is possible that a more prolonged
treatment could result in functional abnormalities in
muscle. However, because statin myopathy can occur
at any time during long-term statin treatment (81)
and most people taking statins over many years do
not experience overt muscle symptoms, this suggests
that this is generally not the case. Thus, it is an
additional susceptibility (e.g., genetic or exercise-
induced SR Ca2þ leak) that reveals myopathy in a
small proportion of the cohort.
CONCLUSIONS
Conditions in which increased SR Ca2þ leak can be
expected should be considered a risk factor when
statins are prescribed. Identifying risk factors un-
derlying statin-induced myopathy is important
because recent modeling experiments have indi-
cated that improving statin adherence by 50% (e.g.,
by preventing statin-induced myopathy) would
prevent twice as many deaths as a 5% reduction in
the cardiovascular risk threshold for statin pre-
scription (82).
ADDRESS FOR CORRESPONDENCE: Dr. Sarah Cala-
ghan, School of Biomedical Sciences, Garstang
Building, University of Leeds, Leeds LS2 9JT, United
Kingdom. E-mail: s.c.calaghan@leeds.ac.uk.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Up to
one-third of patients report statin-associated muscle
symptoms in observational studies. The incidence in ran-
domized controlled trials is much less. In part, this dif-
ference may arise because those susceptible to myopathy
or with indications of myopathy in the run-in phase are
excluded from trials. However, the experience of muscle
pain is subjective, and many patients are primed to expect
this because of patient information leaﬂets and wide-
spread reporting of side effects of statins in the press.
Therefore, an understanding of the mechanism of statin
myopathy and factors that make users more susceptible
to overt muscle pain and weakness (even potentially fatal
rhabdomyolysis) are essential. In this study, we demon-
strated leaky RyRs in skeletal muscle following statin
treatment. Although this by itself did not cause overt
myopathy, it did provide a strong indicator of the popu-
lations who are at real risk of myopathy—those whose
lifestyle or genotype predispose them to SR Ca2þ leak.
This includes patients who undertake regular high-
intensity exercise or have mutations in the RyR1 associ-
ated with malignant hyperthermia. In these individuals,
statins should be used cautiously with consideration of
dose, alternative cholesterol-lowering strategies, and
monitoring of serum creatine kinase levels. However, our
data do support the view that moderate exercise should
be actively encouraged in those who take statins. As well
as the positive effects of exercise on cardiovascular
health, this type of activity appears to limit potentially
harmful effects of statins on skeletal muscle.
TRANSLATIONAL OUTLOOK: There are several bar-
riers to clinical translation of this work. The ﬁrst is the
sheer scale of the problem, because of the number of
people who are (and should be) prescribed statins. Sec-
ond, we have not yet identiﬁed directly the conditions
that precipitate overt myopathy, although our data pro-
vided a strong indication of what these factors may be.
Third, there are currently no cost-effective alternative
antilipidemic agents that match the efﬁcacy of statins for
those at high risk of myopathy. Statins confer additional
therapeutic beneﬁts independent of their ability to lower
serum cholesterol (pleiotropic actions), which are not
evident with other drugs. For example, the recently
licensed PCSK9 inhibitors cost 50 to 100 times more than
generic statins and lack the pleiotropic actions effects of
statins.
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